The long-term therapeutic efficacy of TF on ITP is better than that of glucocorticoids, because fewer adverse side effects are observed for TF than those for glucocorticoids; e.g., neutrophils are decreased by glucocorticoids but not by TF, and immunity inhibition is induced by glucocorticoids but not by TF. The gene discussed is TF; the disease is autoimmune thrombocytopenic purpura.